Listen to Bert Baron of 1450 WCTC of Central New Jersey interview Russell Rothman, Board Chair for Alzheimer’s New Jersey®, discuss the upcoming Walk to Fight Alzheimer's on Sunday October 30th 2016.100% of Your Donation Goes HelpFight Alzheimer’s in [View More]
A little rain never hurt anybody! Thanks to all who participated in our #WalkToFightALZ in Princeton on Sunday, October 9th. Your support for our organization, and the individuals and families impacted by Alzheimer's in New Jersey, means everything. [View More]
Listen to Bert Baron of 1450 WCTC of Central New Jersey interview Ken Zaentz, CEO of Alzheimer’s New Jersey®, discuss the effects of Alzheimer’s and the services available to New Jersey residents offered by Alzheimer’s New Jersey. 100% of [View More]
Listen to Dave Wight’s program The Human Side of Business on Hunterdon Chamber Internet Radio discuss with Julie Shuldner, Vice President of Alzheimer’s New Jersey discuss the challenges of Alzheimer’s and services available to New Jersey residents. [View More]
A beautiful New Jersey day greeted our walkers and participants at our second Walk to Fight Alzheimer's® event at Liberty State Park on Saturday, October 1, 2016. Thank you for supporting and fighting alongside the many individuals and [View More]
What an amazing turnout yesterday at Walk to Fight Alzheimer’s® in Point Pleasant Beach, NJ! Despite the rain, hundreds of walkers and supporters came out with fighting spirits to help put an end to Alzheimer’s disease. Alzheimer’s New [View More]
Learn More about Programs and Services Provided by Alzheimer's New Jersey® Find Programs & Services
Walk to Fight Alzheimer's Southern Regional Walk Point Pleasent Beach Saturday, September 24, 2016 Register Now
Listen to 1450 WCTC Talk Radio The Voice of Central Jersey’s Bert Baron discuss with Julie Schuldner, Vice President of Alzheimer's New Jersey the upcoming Walk to Fight Alzheimer’s.
Though still in the early stages of clinical trials, a new drug, aducanumab, is showing promise in breaking down the amyloid plaques that build up in the brains of individuals diagnosed with Alzheimer's disease. Biogen, the drug’s developer, reported that [View More]
